ESP Block for Inflammatory Bowel Disease

Recruiting in Palo Alto (17 mi)

Overseen by Naveed Siddiqui, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Trial Summary

What is the purpose of this trial?

This will be a prospective, double-blind randomized controlled clinical trial. There will be two arms of treatment: intervention and control group. Preoperatively patients will be allocated at random to receive ultrasound guided bilateral ESP block either with the local anesthetic (intervention group) normal saline (control group). The aim of this study is to examine the effect of ESP block to increase the Quality of Recovery (measured via QoR-15 total score) and decrease opioid consumption.

Research Team

Naveed Siddiqui, MD

Principal Investigator

Associate Professor

Eligibility Criteria

This trial is for patients with Inflammatory Bowel Disease (IBD) who may also have issues with opioid use. Participants should be preparing for surgery and willing to receive an ultrasound-guided ESP block, which is a type of pain management technique.

Inclusion Criteria

I am between 18 and 85 years old and have been diagnosed with IBD.

My health is good to moderately impaired.

I have had laparoscopic surgery for IBD under general anesthesia.

Exclusion Criteria

Pregnant

Concomitant injuries

Known allergies to local anesthetics

Treatment Details

Interventions

• ESP Block (Procedure)

Trial Overview The study tests the effectiveness of the Erector Spinae Plane (ESP) block in improving recovery quality and reducing opioid need after surgery. Patients will randomly get either Ropivacaine (anesthetic) or saline solution in their ESP block before surgery.

Participant Groups

Group I: Intervention group Active Control 1 Intervention

Ultrasound guided bilateral ESP block either with local anesthetic

Group II: Control group Placebo Group 1 Intervention

Ultrasound guided bilateral ESP block either with normal saline

Who Is Running the Clinical Trial?

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Lead Sponsor

Trials

132

Recruited

11,400+

Dr. Anne-Claude Gingras

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Chief Executive Officer

PhD in Functional Proteomics, Canada Research Chair

Dr. Susanna Mak

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Chief Medical Officer since 2004

MD, University of Toronto